Retinal Vein Occlusion Clinical Trial
Official title:
Response of Retinal Vessels to Anti Vascular Endothelial Growth Factor (VEGF) Treatment in Patients With Branch Retinal Vein Occlusion (BRVO)
In a recent study we could show that the early retinal venous vasoconstriction after grid photocoagulation in branch retinal vein occlusion (BRVO) is closely correlated to the visual outcome after three months. This could be of clinical importance, because the degree of vasoconstriction might be an early marker of treatment success, compatible with the idea that hypoxia is the major trigger of VEGF in BRVO. The present study evaluates the response of retinal vessel diameters to anti VEGF treatment with lucentis in patients with BRVO. This is done in an effort to gain insight into the retinal hemodynamic consequences of anti VEGF treatment in BRVO. The hypothesis that anti VEGF treatment is associated with a vasoconstrictor response in retinal vessel in patients with BRVO is tested.
To investigate the response of retinal vessel diameters to lucentis treatment in patients
with BRVO and to correlate these changes with changes in functional outcome after 3 months.
Pilot study in patients scheduled for intravitreal anti-VEGF (Lucentis™) treatment with BRVO
30 patients with BRVO scheduled for intravitreal anti-VEGF treatment Intravitreous
administration of Ranibizumab (Lucentis ™)
Main outcome measure: Retinal vessel diameters
Secondary outcome measures: Retrobulbar flow velocities, best-corrected visual acuity,
macular sensitivity assessed with Microperimetry, objective functional response assessed
with mfERG, anatomic changes in the macula region as assessed with StratusOCT and prototype
of a Cirrus-OCT(which is available at the Department of Ophthalmology, Medical University of
Vienna), angiographical outcomes.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
| Completed |
NCT04592419 -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
|
Phase 3 | |
| Recruiting |
NCT05133791 -
NIR Fluorescence Molecular Imaging of ANXV-800CW in RVO Patients
|
Phase 1 | |
| Withdrawn |
NCT04011358 -
Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study
|
N/A | |
| Completed |
NCT02898480 -
Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning
|
N/A | |
| Recruiting |
NCT01581151 -
Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
|
N/A | |
| Completed |
NCT01428388 -
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
|
N/A | |
| Completed |
NCT00970957 -
Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion
|
Phase 3 | |
| Recruiting |
NCT04075695 -
Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion
|
||
| Recruiting |
NCT03525132 -
Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV)
|
N/A | |
| Recruiting |
NCT03762226 -
Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study
|
||
| Recruiting |
NCT02257333 -
Retinal Thrombosis and Atherosclerosis
|
||
| Recruiting |
NCT04140448 -
Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
|
||
| Active, not recruiting |
NCT05003258 -
Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients With Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection
|
N/A | |
| Terminated |
NCT04707625 -
Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment
|
Phase 4 | |
| Recruiting |
NCT04142164 -
Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections
|
N/A | |
| Completed |
NCT02523339 -
Study of Retinal Oxygenation in Central Retinal Vein Occlusion
|
||
| Active, not recruiting |
NCT01449682 -
Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
|
Phase 3 | |
| Completed |
NCT01568021 -
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
|
N/A | |
| Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 |